Neurobiological Technologies, Inc.  

(Public, OTCMKTS:NTII)   Watch this stock  
Find more results for NTII
0.0000 (0.00%)
Feb 23 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.01 - 0.02
Open     -
Vol / Avg. 0.00/52.00
Mkt cap 283,710.00
P/E 0.02
Div/yield     -
EPS 0.69
Shares 27.02M
Beta -0.48
Inst. own 0%

Key stats and ratios

Q4 (Dec '09) 2009
Net profit margin - 11.85%
Operating margin - 9.40%
EBITD margin - 14.48%
Return on average assets -11.22% 9.21%
Return on average equity -12.28% 14.41%
Employees 4 -
CDP Score - -


2010 Crow Canyon Pl Ste 100
SAN RAMON, CA 94583-1344
United States - Map
+1-925-3593247 (Phone)
+1-302-6365454 (Fax)


Neurobiological Technologies, Inc. (NTI), was previously focused on developing investigational drugs to treat human diseases. On October 27, 2009, the Company’s stockholders approved the dissolution of the Company pursuant to a plan of complete liquidation and dissolution earlier approved by its board of directors on August 27, 2009 (the Plan of Dissolution). As a Company in dissolution, NTI was not allowed to carry on any business except for the purpose of winding down the business and affairs of the Company. On December 17, 2009, the Company filed a certificate of dissolution with the Secretary of State of the State of Delaware (the Certificate of Dissolution). As of June 30, 2010, NTI retains an interest in an investigational drug called XERECEPT, which is a synthetic preparation of Corticotropin-Releasing Factor, a natural human peptide. XERECEPT is being developed by Celtic Pharma as a treatment for swelling around brain tumors and other cancer indications.

Officers and directors

Matthew M. Loar CPA Acting Chief Executive and Financial Officer, Director
Age: 51
William A Fletcher Director
Age: 65
John B. Stuppin Director
Age: 79